~~<i id='DCB5D6E118'><strike id='DCB5D6E118'><tt id='DCB5D6E118'><pre id='DCB5D6E118'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：knowledge 2025-09-06 08:13:19 Page View：4841

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Senators tussle over abortion against the backdrop of a presidential campaign
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

focus

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Anthony Fauci pushes back on GOP claims during Covid hearing

AnthonyFauci,theformerheadoftheNationalInstituteofAllergyandInfectiousDiseases,testifiedbeforeaHouse

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

2:36FloridaGovernorRonDeSantisspeaksatapressconferencetodiscussFlorida'scivicseducationinitiativeofu